TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04968353

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incisally-beveled attachment
Description: Incisally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gingivally-beveled attachment
Description: Gingivally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimized attachment
Description: Optimized attachments will be bonded to teeth before or during orthodontal treatment with clear aligners

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal attachment
Description: Horizontal attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
Study: NCT05869253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The efficacy of Equine Assisted Occupational Therapy, for children with Attention Deficit Hyperactivity Disorder (ADHD) on cognitive-emotional aspects, daily function and participation
Description: : A prospective cohort study with Interrupted Time-Series design will be conducted. Forty participants and their parents who were referred to EAOT will be recruited from the waiting list of Harey Yehuda stables. Assessments will take place at four time points. Time 1: baseline-when referred for EAOT. Time 2: pre-test, before first treatment session, end of 12 week waiting period. Time 3: post-test after 12 weeks of intervention and time 4: post intervention assessment, three months follow up. The intervention will be administered by a licensed EAOT, and assessments will be done by a blinded licensed occupational therapist (OT). Standardized assessment measures will be used to measure EFs, cognitive-emotional and sensory-motor aspects as well as participation at each time point.
Study: NCT04372901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digitally constructed frameworks before implant placement
Description: Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
Study: NCT04743271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Fat Diet
Description: The diet will consist of a breakfast, lunch, dinner, and snack

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-Fat Diet
Description: The diet will consist of a breakfast, lunch, dinner, and snack
Study: NCT05525832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Nasopharyngeal washes with NaCl 0.9%
Study: NCT06405165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: student success
Description: The effect of the flipped education-Jigsaw learning model on the knowledge level of urinary catheter care in nursing students.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: student success
Description: The effect of the flipped education-Jigsaw learning model on the knowledge level of urinary catheter care in nursing students.
Study: NCT05257590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVM-1118
Description: CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
Study: NCT06354348

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: USG, Grip strength, Chair stand test (CST)
Description: Anterior thigh muscle thickness was measured with USG Grip strength was measured with an electronic hand dynamometer Chair stand test (CST) was performed while participants were asked to stand up and sit down from a chair - without arm rest, for five times as quick as possible, with their arms crossed over their chests.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: USG, Grip strength, Chair stand test (CST)
Description: Anterior thigh muscle thickness was measured with USG Grip strength was measured with an electronic hand dynamometer Chair stand test (CST) was performed while participants were asked to stand up and sit down from a chair - without arm rest, for five times as quick as possible, with their arms crossed over their chests.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: USG, Grip strength, Chair stand test (CST)
Description: Anterior thigh muscle thickness was measured with USG Grip strength was measured with an electronic hand dynamometer Chair stand test (CST) was performed while participants were asked to stand up and sit down from a chair - without arm rest, for five times as quick as possible, with their arms crossed over their chests.
Study: NCT05512182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pembrolizumab : 200mg/Q3W/IV infusion/Day 1of each 3-week cycle Neratinib : Week 1: 120 mg, Week 2: 160 mg, Week 3 and onwards: 240 mg/QD/Oral/Once daily Paclitaxel : 175mg/m2 /Q3W/IV infusion/Day 1of each 3-week cycle
Study: NCT05662449

Intervention type: DEVICE
Intervention: Syndesmosis fixation using Activascrew
Description: as described prior
Study: NCT05381233

Intervention type: OTHER
Group type: OTHER
Intervention: Gross motor function classification System (GMFCS)
Description: assessment

Intervention type: OTHER
Group type: OTHER
Intervention: Gross motor function classification System (GMFCS)
Description: assessment

Intervention type: OTHER
Group type: OTHER
Intervention: Gross motor function classification System (GMFCS)
Description: assessment
Study: NCT05216718

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-flap
Description: Mini-flap BABA robotic-thyroidectomy creates flaps up to the cricoid cartilage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional flap
Description: Conventional flap BABA robotic-thyroidectomy creates flaps up to the thyroid cartilage
Study: NCT05381233

Intervention type: OTHER
Group type: OTHER
Intervention: Arabic Version of Zarit burden Inventory measure
Description: assessment
Study: NCT04372901

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digitally constructed frameworks after implant placement
Description: Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement.
Study: NCT05241912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery
Study: NCT05381233

Intervention type: OTHER
Group type: OTHER
Intervention: Arabic Version of Zarit burden Inventory measure
Description: assessment

Intervention type: OTHER
Group type: OTHER
Intervention: Arabic Version of Zarit burden Inventory measure
Description: assessment

Intervention type: OTHER
Group type: OTHER
Intervention: Arabic Version of Chalder Fatigue Scale (CFQ version 11)
Description: assessment

Intervention type: OTHER
Group type: OTHER
Intervention: Arabic Version of Chalder Fatigue Scale (CFQ version 11)
Description: assessment

Intervention type: OTHER
Group type: OTHER
Intervention: Arabic Version of Chalder Fatigue Scale (CFQ version 11)
Description: assessment
Study: NCT05075694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic Touch performed in line with the Therapeutic Touch Practice Procedure included the following steps: centering, assessing, rebalancing, reassessing, reexamining, grounding, and closure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Therapeutic Touch
Description: The control group was administered STT instead of TT for 10 minutes for successive 5 days. The practice was implemented in line with STTPP. The practice was implemented by not centering or intending to help to heal, by moving at a longer distance, and by imitating the TT practice protocol visually.
Study: NCT06387381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSFA
Description: Each subject receives a single intravenous injection of 68Ga-PSFA.
Study: NCT04732923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned intervention - procedure
Description: This study is defined in 3 stages :~STEP 1 : during the cardiac rehabilitation program over 4 weeks 6 minute walk test, questionnaires~STEP 2 : monitoring at 6 months after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires~STEP 3 : monitoring at one year after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires
Study: NCT05370976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytotect®CP
Description: Cytotect®CP in two phases:~Induction phase: 1 ml/kg/week for 4 weeks Maintenance phase: 1 ml/kg/2 weeks for 12 weeks or corticosteroid dose \< 0.5 mg/kg, according to which condition occurs first.~Patients developing CMV infection under Cytotect®CP must be given standard anti-CMV treatment (Gancyclovir or Foscarnet) according to their center procedure. Cytotect®CP will be maintained
Study: NCT05293600

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule 30 min before bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with increased loop gain will be given Acetazolamide 500 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased arousal threshold will be given Trazodone 100 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine and eszopiclone
Description: The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased muscle responsiveness will be given Atomoxetine and Eszopiclone 80 + 3 mg.
Study: NCT06094608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning light treatment
Description: Light therapy via the Re-Timer. Participants will conduct light treatment in the mornings at home for one hour using Re-timer®.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Participants will not make modifications to their activities or sleep schedule.
Study: NCT05302973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: 30 min/day of aerobic exercise added to 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
Study: NCT06554977

Intervention type: OTHER
Intervention: Laboratory
Description: CBC Kidney function (Urea, creatine) Platelets to albumin ratio Albumin /creatine ratio CRP Urine analysis Abdominal us Kidney function , CBC , Albumin will be done at the time of admission i

Intervention type: OTHER
Intervention: Laboratory
Description: CBC Kidney function (Urea, creatine) Platelets to albumin ratio Albumin /creatine ratio CRP Urine analysis Abdominal us Kidney function , CBC , Albumin will be done at the time of admission i
Study: NCT04701853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific abdominal muscle training
Description: Specific abdominal muscle training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Care according to each center.
Study: NCT06345170

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The DIR/Floortime™ Therapy Program
Description: The DIR/Floortime™ therapy program will be applied by the therapist in the clinic for 50 minutes, 2 days a week for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The DIR/Floortime™ Therapy Program
Description: The DIR/Floortime™ therapy program will be applied by the therapist in the clinic for 50 minutes, 2 days a week for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program
Description: The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program will be applied by the parents at home, 2 days a week, for an average of 30 minutes a day, for 12 weeks
Study: NCT05384470

Intervention type: DRUG
Group type: OTHER
Intervention: Marihuana
Description: Two doses of marijuana given.

Intervention type: DEVICE
Group type: OTHER
Intervention: BID2 Instrument - breathalyzer
Description: The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.
Study: NCT04124120

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single arterial graft
Description: This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple arterial grafting
Description: This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
Study: NCT06138353

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Shuxuening injection or placebo
Description: Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuxuening injection or placebo
Description: Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
Study: NCT06181916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amp
Description: Amp is a virtual support system mHealth app that provides information and social support to help young Black men who have sex with men (YBMSM) living with HIV achieve better HIV care continuum outcomes and overall well-being.
Study: NCT05038618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(S protein with adjuvant)
Description: Approximately 400 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study: NCT06337162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: 400 mg Tablet
Study: NCT06231914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StarWalker® PQX
Description: Third-generation ASP-powered technology for ultra performance: Highest pico power \& energy, shortest pico pulse width, wide range of laser wavelengths, exceptional spot size capabilities, largest fluence spectrum for flat-top handpieces
Study: NCT06278870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: disitamab vedotin 2mg/kg iv q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: pyrotinib 400mg po q28d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: trastuzumab 8mg/kg for the first cycle, 6mg/kg for subsequent treatments iv q21d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: trastuzumab 8mg/kg for the first cycle, 6mg/kg for subsequent treatments iv q21d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: pertuzumab 840mg for the first cycle, 420mg for subsequent treatments iv q21d
Study: NCT05726448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth solution
Description: Mobile-friendly nutrition education platform
Study: NCT04836546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose meter
Description: First phase: SMBG for 6 months
Study: NCT06278870

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taxane drug
Description: Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer guideline recommendations
Study: NCT04836546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eversense CGM System
Description: Second phase: CGM for 6 months
Study: NCT05145803

Intervention type: DEVICE
Intervention: Polyvinylalcohol strip [diagnostic]
Description: The investigators will measure SARS-CoV-2 in exhaled breath of asymptomatic and symptomatic persons using PVA test strips embedded in face masks (FMS) - an innovative, non-invasive method for detection of SARS-CoV-2 in exhaled air. Utilizing this approach, the study aims to utilize the test results extracted from the masks to identify risk factors for SARS-CoV-2 transmission and timing of infectious period in exposed people (pre-symptomatic, asymptomatic, and symptomatic).
Study: NCT05953207

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical hypnosis
Description: Hypnosis intervention with specific suggestions (i.e., patient's own dreamlike mentation)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Of Care
Description: Sleep hygiene and safety education session
Study: NCT06107985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured exercise program
Description: This intervention will be based on shoulder kinetic control, load modification exercises and lumbopelvic stabilization with core stability exercises which is not a part of conventional exercise program for shoulder impingement syndrome patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise Program
Description: Conventional exercise program for shoulder impingement syndrome patients
Study: NCT06277856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer interaction/control
Description: This study was planned as a randomised controlled study with a two-group pretest and posttest design.
Study: NCT04743440

Intervention type: DEVICE
Intervention: Bronchoscopic endotracheal intubation through a supraglottic airway device
Description: Prior to trial commencement, participants will be asked to watch a video demonstrating preparation and conduction of the procedure (bronchoscopic endotracheal intubation through a supraglottic airway device) in a patient not involved in the project. Afterwards they will submit an online test, examining knowledge of the procedure relating to the procedure checklist. After participants have watched the demonstration video and submitted the online test, trial investigator will demonstrate the procedure in the manikin; subsequently, they have the opportunity to train the procedure in the manikin with both Igel and Auragain - training estimated to take less than 30 minutes. Afterwards, they will have the opportunity to train the procedure on manikins, on their own discretion, as per usual standards for maintaining airway competence at the Anaesthesiology Department.
Study: NCT05844735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Tablet
Study: NCT06154148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sustained Diagonal Flexion positioning
Description: This position is a semi reclined positioning, the infant is off-center and semi-reclined on the mother's chest its body-axis is slightly flexed, with the limbs retracted in a preventive posture and the head in line with the body axis, moderately externally rotated hips in flexion-abduction, with adducted shoulders. The infant's head turns toward the mother's face and is located between the nipple and the clavicule. Their arms and legs are flexed,in a naturally adopted asymmetrical tonic neck posture, according to the infant's term and comfort. The infant is naked and positioned inside the mother's clothes.
Study: NCT06109077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Levator ani release
Description: Patients will be treated with levator ani release exercises for pain (3 sets with 10 repetitions 3 times per week for 6 weeks).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post isometric relaxion
Description: Patients will be treated with Post isometric relaxation exercise and hold contractions for 10 seconds over 5 to 12 repetitions, 3 times per week for 6 weeks